Caveolin-1 and-2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease

被引:34
作者
van Helmond, Z. K. [1 ]
Miners, J. S. [1 ]
Bednall, E. [1 ]
Chalmers, K. A. [1 ]
Zhang, Y. [1 ]
Wilcock, G. K. [1 ]
Love, S. [1 ]
Kehoe, P. G. [1 ]
机构
[1] Univ Bristol, Dementia Res Grp, Inst Clin Neurosci, Frenchay Hosp, Bristol BS16 1LE, Avon, England
关键词
Alzheimer's disease; amyloid beta peptide; caveolin-1; caveolin-2; cerebral amyloid angiopathy; tunica media;
D O I
10.1111/j.1365-2990.2006.00815.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cerebral amyloid angiopathy (CAA) affects over 90% of patients with Alzheimer's disease (AD) and increases the risk of cerebral haemorrhage and infarction. Caveolae - cholesterol-enriched plasmalemmal microinvaginations - are implicated in the production of amyloid beta peptide (A beta). Caveolin-1 (CAV-1) is essential for the formation of caveolae. Caveolin-2 (CAV-2) is expressed at the plasma membrane only when in a stable hetero-oligomeric complex with CAV-1. CAV-1 and CAV-2 are highly co-expressed by endothelium and smooth muscle. Recent studies suggest that down-regulation of CAV-1 causes a reduction in alpha-secretase activity and consequent accumulation of A beta. We have used quantitative immunohistochemical techniques to assess the relationship between CAV-1 and CAV-2 with respect to A beta accumulation in the cerebral vasculature in a series of post mortem brains. CAV-1 and CAV-2 were co-expressed within the tunica media and endothelium of cerebral blood vessels. There were regional differences in CAV-1 immunolabelling, which was significantly greater in the frontal cortex and white matter than in the parietal lobe (in both control and AD cases) or the temporal lobe (in AD alone). However, CAV-1 labelling in AD did not differ from that in controls in any of the three lobes examined. Assessment of CAV-1 labelling in relation to the severity of CAA showed CAV-1 to be significantly increased in the frontal white matter in a subgroup of AD cases with absent/mild CAA compared with controls with absent/mild CAA and to AD cases with moderate/severe CAA, but the latter groups did not show significant differences from one another. CAV-1 labelling did not vary with age, gender, APOE genotype, post mortem delay or brain weight. Only segments of blood vessels with particularly abundant A beta and extensive loss of smooth muscle actin showed loss of CAV-1 and CAV-2 from the tunica media. Within these vessels endothelial CAV-1 was preserved and discontinuous CAV-2 labelling was noted along the outer aspect of the vessel wall. Our findings suggest that alterations in the expression of vascular CAV-1 and CAV-2 are unlikely to play a role in the development of CAA in AD.
引用
收藏
页码:317 / 327
页数:11
相关论文
共 50 条
  • [21] Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer's Disease: A PET Study
    Planton, Melanie
    Saint-Aubert, Laure
    Raposo, Nicolas
    Payoux, Pierre
    Salabert, Anne-Sophie
    Albucher, Jean-Francois
    Olivot, Jean-Marc
    Peran, Patrice
    Pariente, Jeremie
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 73 (04) : 1607 - 1614
  • [22] Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy
    Roy O. Weller
    Delphine Boche
    James A. R. Nicoll
    Acta Neuropathologica, 2009, 118
  • [23] Amyloid β peptide 1–42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology
    Johannes Attems
    Felix Lintner
    Kurt A. Jellinger
    Acta Neuropathologica, 2004, 107 : 283 - 291
  • [24] Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease
    van den Berg, Emma
    Nilsson, Johanna
    Kersten, Iris
    Brinkmalm, Gunnar
    de Kort, Anna M.
    Klijn, Catharina J. M.
    Schreuder, Floris H. B. M.
    Jakel, Lieke
    Gobom, Johan
    Portelius, Erik
    Zetterberg, Henrik
    Brinkmalm, Ann
    Blennow, Kaj
    Kuiperij, H. Bea
    Verbeek, Marcel M.
    JOURNAL OF ALZHEIMERS DISEASE, 2023, 92 (02) : 467 - 475
  • [25] Differences in the cerebral amyloid angiopathy proteome in Alzheimer's disease and mild cognitive impairment
    Leitner, Dominique
    Kavanagh, Tomas
    Kanshin, Evgeny
    Balcomb, Kaleah
    Pires, Geoffrey
    Thierry, Manon
    Suazo, Jianina I.
    Schneider, Julie
    Ueberheide, Beatrix
    Drummond, Eleanor
    Wisniewski, Thomas
    ACTA NEUROPATHOLOGICA, 2024, 148 (01)
  • [26] Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis
    Castellani, RJ
    Smith, MA
    Perry, G
    Friedland, RP
    NEUROBIOLOGY OF AGING, 2004, 25 (05) : 599 - 602
  • [27] Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease
    Roy O Weller
    Stephen D Preston
    Malavika Subash
    Roxana O Carare
    Alzheimer's Research & Therapy, 1
  • [28] Increased caveolin-1 expression in Alzheimer's disease brain
    Gaudreault, SB
    Dea, D
    Poirier, J
    NEUROBIOLOGY OF AGING, 2004, 25 (06) : 753 - 759
  • [29] Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy
    Miners, J. S.
    Ashby, E.
    Van Helmond, Z.
    Chalmers, K. A.
    Palmer, L. E.
    Love, S.
    Kehoe, P. G.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2008, 34 (02) : 181 - +
  • [30] Imaging features of small vessel disease in cerebral amyloid angiopathy among patients with Alzheimer's disease
    Nagaraja, Nandakumar
    Dekosky, Steven
    Duara, Ranjan
    Kong, Lan
    Wang, Wei-en
    Vaillancourt, David
    Albayram, Mehmet
    NEUROIMAGE-CLINICAL, 2023, 38